نتایج جستجو برای: fgfr2

تعداد نتایج: 1274  

2017
Lixing W. Reneker Lanlan Wang Rebecca T. Irlmeier Andrew J. W. Huang

Purpose Little is known about the signaling mechanisms controlling meibomian gland (MG) homeostasis and the pathogenic processes leading to MG atrophy and dysfunction in dry eye disease (DED). We investigated the role of fibroblast growth factor receptor 2 (FGFR2) in the MG homeostasis of adult mice. Methods A triple transgenic mouse strain (Krt14-rtTA; tetO-Cre; Fgfr2flox/flox), referred to ...

2013
Liang Xie Lin Zhang Xiaolu Yin Lili Tang Xiuhua Zhang Yanping Xu Kunji Liu Minhua Zhou Beirong Gao Danping Shen Lianhai Zhang Jiafu Ji Paul R. Gavine Jingchuan Zhang Elaine Kilgour Xiaolin Zhang Qunsheng Ji

Purpose: FGFR gene aberrations are associated with tumor growth and survival. We explored the role of FGFR2 amplification in gastric cancer and the therapeutic potential of AZD4547, a potent and selective ATPcompetitive receptor tyrosine kinase inhibitor of fibroblast growth factor receptor (FGFR)1–3, in patients with FGFR2-amplified gastric cancer. Experimental Design: Array-comparative genomi...

2016
Hyewon Woo Jung Min Ko Choong Ho Shin Sei Won Yang

#201750). FGFR2 mutations show variable clinical penetrance and patients with the same FGFR2 mutation can exhibit diverse clinical features. Therefore, FGFR2-related craniosynostosis syndromes are usually named according to the accompanying extra-cranial manifestations. ABS is a rare type of craniosynostosis syndrome. ABS is typically distinguished by systemic bony fusions of skull sutures and ...

Journal: :Molecular cancer therapeutics 2014
Nuria Eritja Mónica Domingo Maria Alba Dosil Cristina Mirantes Maria Santacana Joan Valls Antonio Llombart-Cussac Xavier Matias-Guiu Xavier Dolcet

Mutations in fibroblast growth factor receptor 2 (FGFR2) have been recently described as a molecular-specific feature in endometrial carcinomas and the presence of activated FGFR2 mutations is associated with poor prognosis. For that reason, inhibition of FGFR2 could be a therapeutic target in the treatment of endometriod carcinomas. In this work, we investigated the antitumoral activity of dov...

Journal: :Cancer research 2015
Junko Tanizaki Dalia Ercan Marzia Capelletti Michael Dodge Chunxiao Xu Magda Bahcall Erin M Tricker Mohit Butaney Antonio Calles Lynette M Sholl Peter S Hammerman Geoffrey R Oxnard Kwok-Kin Wong Pasi A Jänne

The discovery of oncogenic driver mutations and the subsequent developments in targeted therapies have led to improved outcomes for subsets of lung cancer patients. The identification of additional oncogenic and drug-sensitive alterations may similarly lead to new therapeutic approaches for lung cancer. We identify and characterize novel FGFR2 extracellular domain insertion mutations and demons...

2013
J. Liu T.-G. Kwon H. K. Nam N. E. Hatch

We recently reported that cranial bones of Fgfr2(C342Y/+) craniosynostotic mice are diminished in density when compared to those of wild type mice, and that cranial bone cells isolated from the mutant mice exhibit inhibited late stage osteoblast differentiation. To provide further support for the idea that craniosynostosis-associated Fgfr mutations lead to cell autonomous defects in osteoblast ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Tetsuo Kondo Xuegong Zhu Sylvia L Asa Shereen Ezzat

PURPOSE Fibroblast growth factor (FGF) signals play fundamental roles in development and tumorigenesis. Thyroid cancer is an example of a tumor with nonoverlapping genetic mutations that up-regulate mitogen-activated protein kinase. We reported recently that FGF receptor 2 (FGFR2) is down-regulated through extensive DNA promoter methylation in thyroid cancer. Reexpression of the FGFR2-IIIb isof...

Journal: :Molecular cancer research : MCR 2009
Michael G Gartside Huaibin Chen Omar A Ibrahimi Sara A Byron Amy V Curtis Candice L Wellens Ana Bengston Laura M Yudt Anna V Eliseenkova Jinghong Ma John A Curtin Pilar Hyder Ursula L Harper Erica Riedesel Graham J Mann Jeffrey M Trent Boris C Bastian Paul S Meltzer Moosa Mohammadi Pamela M Pollock

We report that 10% of melanoma tumors and cell lines harbor mutations in the fibroblast growth factor receptor 2 (FGFR2) gene. These novel mutations include three truncating mutations and 20 missense mutations occurring at evolutionary conserved residues in FGFR2 as well as among all four FGFRs. The mutation spectrum is characteristic of those induced by UV radiation. Mapping of these mutations...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2006
Sebastian Oltean Brian S Sorg Todd Albrecht Vivian I Bonano Robert M Brazas Mark W Dewhirst Mariano A Garcia-Blanco

In epithelial cells, alternative splicing of fibroblast growth factor receptor 2 (FGFR2) transcripts leads to the expression of the FGFR2(IIIb) isoform, whereas in mesenchymal cells, the same process results in the synthesis of FGFR2(IIIc). Expression of the FGFR2(IIIc) isoform during prostate tumor progression suggests a disruption of the epithelial character of these tumors. To visualize the ...

Journal: :Molecular cell 2009
Claude C Warzecha Trey K Sato Behnam Nabet John B Hogenesch Russ P Carstens

Cell-type-specific expression of epithelial and mesenchymal isoforms of Fibroblast Growth Factor Receptor 2 (FGFR2) is achieved through tight regulation of mutually exclusive exons IIIb and IIIc, respectively. Using an application of cell-based cDNA expression screening, we identified two paralogous epithelial cell-type-specific RNA-binding proteins that are essential regulators of FGFR2 splici...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید